CORRIGENDUM
Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas aeruginosa
Kosuke Kosai1, *, Norihito Kaku2, Naoki Uno2, Tomomi Saijo3, Yoshitomo Morinaga2, Yoshifumi Imamura3, Hiroo Hasegawa1, Taiga Miyazaki4, Koichi Izumikawa4, Hiroshi Mukae3, Katsunori Yanagihara2
Article Information
Identifiers and Pagination:
Year: 2018Volume: 12
First Page: 321
Last Page: 322
Publisher ID: TOMICROJ-12-321
DOI: 10.2174/1874285801812010321
Article History:
Electronic publication date: 28/09/2018Collection year: 2018
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas Aeruginosa
The Open Microbiology Journal, 2017, 11-92
The correct Table 2 is mentioned below:
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
OR | 95%CI | P | OR | 95%CI | P | |
Resistance to FQs | ||||||
Transplantation | 1.74 | 0.80-3.78 | 0.161 | |||
Use of corticosteroids (≥5 mg/day) or other immunosuppressive agents | 1.81 | 0.93-3.52 | 0.082 | |||
Surgery | 0.65 | 0.35-1.21 | 0.173 | |||
Exposure to first-generation cephalosporins | 0.60 | 0.30-1.19 | 0.143 | |||
Exposure to second-generation cephalosporins | 0.28 | 0.08-1.01 | 0.051 | |||
Exposure to FQs | 5.30 | 2.52-11.14 | <0.001 | 5.73 | 2.67-12.30 | <0.001 |
Exposure to AGs | 3.92 | 1.30-11.87 | 0.016 | |||
MBL production | 6.67 | 1.78-24.91 | 0.005 | 7.90 | 2.01-31.04 | 0.003 |
Resistance to AGs | ||||||
Use of anticancer drugs | 2.57 | 0.64-10.40 | 0.184 | |||
Use of urinary catheter | 0.42 | 0.13-1.38 | 0.152 | |||
Exposure to antipseudomonal penicillins | 0.24 | 0.05-1.14 | 0.073 | 0.16 | 0.03-0.89 | 0.036 |
Exposure to AGs | 6.04 | 1.59-23.00 | 0.008 | 9.00 | 1.92-42.19 | 0.005 |
MBL production | 7.35 | 1.89-28.65 | 0.004 | 8.49 | 1.87-38.52 | 0.006 |
The original table provided was:
Resistance to FQs | Resistance to AGs | ||||||
---|---|---|---|---|---|---|---|
All strains (n = 169) |
Yes (n = 66) |
No (n = 103) |
P |
Yes (n = 12) |
No (n= 157) |
P | |
Resistance to antibiotics | |||||||
Piperacillin1) | 36 (21.3) | 21 (31.8) | 15 (14.6) | 0.003 | 4 (33.3) | 32 (20.4) | 0.347 |
Ceftazidime1) | 53 (31.4) | 33 (50.0) | 20 (19.4) | <0.001 | 8 (66.7) | 45 (28.7) | 0.022 |
Cefepim | 38 (22.5) | 28 (42.4) | 10 (9.7) | <0.001 | 7 (58.3) | 31 (19.7) | 0.006 |
Aztreonam | 91 (53.8) | 45 (68.2) | 46 (44.7) | 0.004 | 9 (75.0) | 82 (52.2) | 0.146 |
Ciprofloxacin1) | 49 (29.0) | - | - | - | 8 (66.7) | 41 (26.1) | 0.011 |
Levofloxacin | 60 (35.5) | - | - | - | 6 (50.0) | 54 (34.4) | 0.350 |
Gentamicin1) | 12 (7.1) | 8 (12.1) | 4 (3.9) | 0.042 | - | - | - |
Amikacin1) | 4 (2.4) | 3 (4.5) | 1 (1.0) | 0.274 | - | - | - |
MBL production | 14 (8.3) | 11 (16.7) | 3 (2.9) | 0.003 | 4 (33.3) | 10 (6.4) | 0.010 |
FQs, fluoroquinolones; AGs, aminoglycosides; MBL, metallo-β-lactamase 1)Minimum inhibitory concentrations (MICs) for piperacillin, ceftazidime, ciprofloxacin, gentamicin and amikacin were not measured in eleven, one, one, one, and thirteen strains, respectively.